Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 12/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 8/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 9/20 | 0.43 |
| ▸ | USP2 | O75604 | 4/20 | 0.43 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 4/20 | 0.42 |
| ▸ | TSHR | P16473 | 4/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 7/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 5/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15836945 | 0.85 | PDK2 (0.46) | MEN1KMT2APDK2 | |
| SCHEMBL15836738 | 0.84 | BACE1 (0.47) | CYP3A4CYP2C19MAPK1MEN1KMT2A | |
| SCHEMBL15969314 | 0.82 | SMN1; SMN2 (0.40) | CYP2C19PDK2CYP2C9ALDH1A1HPGD | |
| SCHEMBL15837085 | 0.80 | FASN (0.40) | PDK2ALDH1A1 | |
| SCHEMBL20221103 | 0.77 | BACE1 (0.43) | CYP3A4CYP2C19MAPK1MEN1KMT2A | |
| SCHEMBL30676372 | 0.76 | CYP3A4 (0.40) | CYP3A4CYP2C19MAPK1MEN1KMT2A | |
| SCHEMBL29341383 | 0.76 | CYP3A4 (0.40) | CYP3A4CYP2C19MAPK1MEN1KMT2A | |
| SCHEMBL15837092 | 0.76 | CYP1A2 (0.42) | CYP3A4PDK2HIF1ACYP2D6ALDH1A1 | |
| SCHEMBL2596388 | 0.74 | ABHD6 (0.53) | — | |
| SCHEMBL204595 | 0.73 | PDK2 (0.43) | PDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220135609-A1 | Mannose Derivatives for Treating Bacterial Infections | VERTEX PHARMA (US) | 2022-05-05 | — | — | US | disclosed |
| US-10913761-B2 | 2,7-dibromospiro[fluorene-9,4′-piperidine] compounds | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-02-09 | — | — | US | disclosed |
| US-10913761-B2 | 2,7-dibromospiro[fluorene-9,4′-piperidine] compounds | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-02-09 | — | — | US | disclosed |
| US-20200270293-A1 | Mannose Derivatives for Treating Bacterial Infections | VERTEX PHARMACEUTICALS (CANADA) INCORPORATED (CA) | 2020-08-27 | — | — | US | disclosed |
| US-20200270293-A1 | Mannose Derivatives for Treating Bacterial Infections | VERTEX PHARMACEUTICALS (CANADA) INCORPORATED (CA) | 2020-08-27 | — | — | US | disclosed |
| US-10669298-B2 | Mannose derivatives for treating bacterial infections | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2020-06-02 | — | — | US | disclosed |
| US-10669298-B2 | Mannose derivatives for treating bacterial infections | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2020-06-02 | — | — | US | disclosed |
| US-20190106450-A1 | Mannose Derivatives for Treating Bacterial Infections | VERTEX PHARMACEUTICALS INCORPORATED | 2019-04-11 | — | — | US | disclosed |
| US-20190106450-A1 | Mannose Derivatives for Treating Bacterial Infections | VERTEX PHARMACEUTICALS INCORPORATED | 2019-04-11 | — | — | US | disclosed |
| EP-3388441-A1 | MANNOSE DERIVATIVES FOR TREATING BACTERIAL INFECTIONS | Vertex Pharmaceuticals Incorporated (US) | 2018-10-17 | — | — | EP | disclosed |
| US-9598454-B2 | Mannose derivatives for treating bacterial infections | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2017-03-21 | — | — | US | disclosed |
| US-9598454-B2 | Mannose derivatives for treating bacterial infections | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2017-03-21 | — | — | US | disclosed |
| US-9598454-B2 | Mannose derivatives for treating bacterial infections | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2017-03-21 | — | — | US | disclosed |
| US-20160235775-A1 | Mannose Derivatives for Treating Bacterial Infections | VERTEX PHARMACEUTICALS (CANADA) INCORPORATED (CA) | 2016-08-18 | — | — | US | disclosed |
| US-20160235775-A1 | Mannose Derivatives for Treating Bacterial Infections | VERTEX PHARMACEUTICALS (CANADA) INCORPORATED (CA) | 2016-08-18 | — | — | US | disclosed |
| US-20160235775-A1 | Mannose Derivatives for Treating Bacterial Infections | VERTEX PHARMACEUTICALS (CANADA) INCORPORATED (CA) | 2016-08-18 | — | — | US | disclosed |
| US-20140243283-A1 | MANNOSE DERIVATIVES FOR TREATING BACTERIAL INFECTIONS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-08-28 | — | — | US | disclosed |
| US-20140243283-A1 | MANNOSE DERIVATIVES FOR TREATING BACTERIAL INFECTIONS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-08-28 | — | — | US | disclosed |
| US-20140243283-A1 | MANNOSE DERIVATIVES FOR TREATING BACTERIAL INFECTIONS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-08-28 | — | — | US | disclosed |
| WO-2014100158-A1 | MANNOSE DERIVATIVES FOR TREATING BACTERIAL INFECTIONS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140243283-A1 | MANNOSE DERIVATIVES FOR TREATING BACTERIAL INFECTIONS | MPI, MANBA, MAN2A1 | CYP3A4 3435/4885CYP2C19 2197/4885MAPK1 614/4885 |
| US-20160235775-A1 | Mannose Derivatives for Treating Bacterial Infections | MPI, MANBA, MAN2A1 | CYP3A4 3435/4885CYP2C19 2197/4885MAPK1 614/4885 |
| US-20190106450-A1 | Mannose Derivatives for Treating Bacterial Infections | MPI, MANBA, MAN2A1 | CYP3A4 3435/4885CYP2C19 2197/4885MAPK1 614/4885 |
| US-10913761-B2 | 2,7-dibromospiro[fluorene-9,4′-piperidine] compounds | DHPS, CFTR, FDPS | CYP3A4 838/4885CYP2C19 97/4885MAPK1 3831/4885 |
| US-20220135609-A1 | Mannose Derivatives for Treating Bacterial Infections | MPI, MANBA, MAN2A1 | CYP3A4 3435/4885CYP2C19 2197/4885MAPK1 614/4885 |
| US-10669298-B2 | Mannose derivatives for treating bacterial infections | MPI, MANBA, MAN2A1 | CYP3A4 3435/4885CYP2C19 2197/4885MAPK1 614/4885 |
| US-20200270293-A1 | Mannose Derivatives for Treating Bacterial Infections | MPI, MANBA, MAN2A1 | CYP3A4 3435/4885CYP2C19 2197/4885MAPK1 614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.